EAC 2021 Update in Allergy, Asthma and Immunology

June 3, 2021 to June 6, 2021

The EAC 2021 Update in Allergy, Asthma & Immunology meeting will provide learners with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. Learners will not only gain insights with regard to selecting the best therapeutic alternative for each patient, but they will also have the opportunity to develop novel strategies designed to enhance therapeutic adherence through shared decision making. The format will incorporate problem based learning, uniquely designed to interface with lectures in context to the core issues relevant to the cases.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 14.25 contact hours.

Commercial Support
This activity is supported in part by independent medical education grant from Stallergenes Greer.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1. Describe the burden of illness attributable to allergic diseases
  2. Define severe asthma and describe the major phenotypes
  3. Outline an approach to the use of biologics for allergic diseases
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

Course summary
Available credit: 
  • 14.25 AMA PRA Category 1 Credit™
  • 14.25 Attendance
  • 14.25 CBRN
Course opens: 
06/03/2021
Course expires: 
12/31/2023
Event starts: 
06/03/2021 - 4:00pm
Event ends: 
06/06/2021 - 10:00am
Rating: 
0

Aleena Banerji, MD – Speaker
Advisory Board – Shire, CSL Behring, BioCryst, Salix, Pharvaris, Kalvista
Research Grant – BioCryst, Shire
Consultant- Pharvaris, Kalvista

Mark Boguniewicz, MD – Speaker
Investigator– Regeneron, Incyte
Consultant – AbbVie
Advisory Board – Eli Lilly, Janssen, LEO Pharma, Pfizer, Regeneron, Sanofi 

Don Bukstein, MD – Speaker
Speaker – AstraZeneca, Teva, Sanofi, Regeneron

William Corrao, MD – Planner, CME Moderator
Speaker – GlaxoSmithKline, Boehringer Ingelheim

Ray Davis, MD – Speaker
Consultant – Baxalta, Teva, Shire/Takeda, Genentech, Novartis, Circassia, DBV Technologies, Maculogix, Sanofi
Speaker – ALK, DBV Technologies, Novartis

Anne Ellis, MD – Speaker
Speaker – ALK Abello, AstraZeneca, Aralez, Medexus 
Advisory Board – ALK Abello, AstraZeneca, Aralez, Bayer, Bausch Health, Leo Pharma, Merck, Mylan, Novartis, Pfizer, Regeneron, Sanofi 
Independent Contractor– ALK Abello, AstraZeneca, Aralez, Bayer, Medexus, Novartis, Regeneron, Sanofi

Dennis Ledford, MD – Speaker
Speaker – AstraZeneca, Sanofi, GlaxoSmithKline, ALK, Boehringer Ingelheim, Genentech, Novartis, Regeneron
Advisory Board – AstraZeneca, BioCryst, 
Investigator – AstraZeneca, GlaxoSmithKline
Data Safety Committee – Galderma
Author - AstraZeneca
Consultant - BioCryst
  
Harold Nelson, MD – Speaker
Author – ALK
Advisory Board – ALK

Christine Radojicic, MD – Speaker
Speaker – CSL Behring
Advisory Board – CSL Behring, BioCryst, Takeda

Robert Settipane, MD – CME Planner/Moderator
Independent Contractor - AstraZeneca, BioCryst, Genentech, GlaxoSmithKline, Regeneron, Teva
 

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Allergy Conference (EAC).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 14.25 AMA PRA Category 1 Credit™
  • 14.25 Attendance
  • 14.25 CBRN
Please login or create an account to take this course.